Eris Lifesciences Limited

12%

SEGMENT – Q4 AND FY26 FINANCIAL HIGHLIGHTS • Q4 DBF Q4 DBF FY26 DBF FY26 DBF Revenue growth = 12% and EBIDTA growth =10% with a 37% margin Revenue growth = 12% and EBIDTA growth = 10% with a 37% m

10%

INANCIAL HIGHLIGHTS • Q4 DBF Q4 DBF FY26 DBF FY26 DBF Revenue growth = 12% and EBIDTA growth =10% with a 37% margin Revenue growth = 12% and EBIDTA growth = 10% with a 37% margin Revenue growth =

37%

GHLIGHTS • Q4 DBF Q4 DBF FY26 DBF FY26 DBF Revenue growth = 12% and EBIDTA growth =10% with a 37% margin Revenue growth = 12% and EBIDTA growth = 10% with a 37% margin Revenue growth =11% and EBI

11%

with a 37% margin Revenue growth = 12% and EBIDTA growth = 10% with a 37% margin Revenue growth =11% and EBIDTA growth = 12% with a 37% margin Revenue growth = 11% and EBIDTA growth = 12% with a 37%

36.5%

margin Revenue growth = 11% and EBIDTA growth = 12% with a 37% margin EBIDTA margin expands from 36.5% in FY25 to 37% in FY26 EBIDTA margin expands from 36.5% in FY25 to 37% in FY26 DBF REVENUE (Rs. C

Rs. 671

FY25 FY25 FY26 FY26 Q4 FY25 Q4 FY25 Q4 FY26 Q4 FY26 FY25 FY25 FY26 FY26 • Q4 Revenue = Rs. 671 cr. – 12% growth yoy • Q4 Revenue = Rs. 671 cr. -12% growth yoy • FY26 Revenue = Rs. 2,778 cr. – 11

Rs. 2,778

Revenue = Rs. 671 cr. – 12% growth yoy • Q4 Revenue = Rs. 671 cr. -12% growth yoy • FY26 Revenue = Rs. 2,778 cr. – 11% growth yoy • FY26 Revenue = Rs. 2,778 cr. -11% growth yoy • Q4 EBIDTA = Rs. 246 cr. ~ 10

Rs. 246

nue = Rs. 2,778 cr. – 11% growth yoy • FY26 Revenue = Rs. 2,778 cr. -11% growth yoy • Q4 EBIDTA = Rs. 246 cr. ~ 10% growth yoy • Q4 EBIDTA = Rs. 246 cr..- 10% growth yoy (lower due to Sema pre-launch expe

Rs. 1,026

y (lower due to Sema pre-launch expenses) (lower due to Sema pre-launch expenses) • FY26 EBIDTA = Rs. 1,026 cr. – 12% growth yoy • FY26 EBIDTA = Rs. 1,026 cr. -12% growth yoy • EBIDTA Margin: 36.5% in FY25 t

37.0%

. – 12% growth yoy • FY26 EBIDTA = Rs. 1,026 cr. -12% growth yoy • EBIDTA Margin: 36.5% in FY25 to 37.0% in FY26 • EBIDTA Margin: 36.5% in FY25 to 37.0% in FY26 Source – Unaudited Financial Statements S

Rs. 55

TS AND MISSES OF FY26 Key Misses Key Misses What worked well What worked well • Revenue loss ~ Rs. 55-60 cr. due to • Revenue loss - Rs. 55-60 cr. due to abandoned/ delayed new launches abandoned/ de

Rs. 50

ed to FY27 on account of regulatory delays FY27 on account of regulatory delays • Revenue loss ~ Rs. 50 cr. in Insulins due • Revenue loss - Rs. 50 cr. in Insulins due to supply constrains, on account